Memotal (Piracetam)

Piracetam enhances neuronal membrane fluidity, modulates ion‑channel activity and increases cerebral blood flow. It promotes neuroplasticity by facilitating long‑term potentiation and up‑regulates acetylcholine and glutamate receptors, which together improve synaptic transmission and metabolic efficiency in the central nervous system.

The dosage of Memotal is determined individually by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and route of administration. Healthcare professionals set the appropriate regimen according to current clinical guidelines.

Safety data for piracetam during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Memotal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Memotal (piracetam) belongs to the racetam class of nootropics, which have a longer clinical history than newer agents such as aniracetam or oxiracetam. While all racetams aim to enhance cognition, piracetam is the most widely studied and is available in injectable form for rapid systemic exposure.

Memotal should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and discard any solution that appears discolored or contains particles.

Memotal is administered by a qualified healthcare professional via intramuscular or intravenous injection. The exact route, volume and infusion rate are prescribed based on the patient’s clinical condition and are performed in a setting equipped for sterile injection techniques.

Serious risks associated with Memotal include allergic reactions that may progress to anaphylaxis, worsening of seizure activity in susceptible individuals, significant blood pressure changes, and rare thrombotic events at the injection site. Immediate medical attention is required if any of these occur.

Memotal should be avoided in patients with known hypersensitivity to piracetam or any excipients, in individuals with uncontrolled hypertension, active bleeding disorders, or severe renal or hepatic impairment unless dose adjustments are made. Pregnant or breastfeeding women should only use it when clearly indicated by a physician.